Research & Education

BCRX Fair Value: BioCryst Pharmaceuticals Deep Dive

2026-07-10 · fairvalue-calculator.com

By Dr. Peter Klein, BA · Founder

BioCryst Pharmaceuticals Inc Fair Value Analysis

BioCryst Pharmaceuticals Inc (BCRX) currently trades at USD 11.11, while our models calculate a fair value of USD 17.33. This implies substantial upside of +56.0% with a Quality Score of 70/100, leading to our verdict that the stock is undervalued.

What BioCryst Pharmaceuticals Does

BioCryst Pharmaceuticals develops and commercializes medicines for rare diseases. Its flagship product, ORLADEYO (berotralstat), is an oral once-daily treatment for hereditary angioedema (HAE) that has driven consistent revenue growth. The company also markets RAPIVAB for influenza and maintains a pipeline focused on complement-mediated and other rare disorders. Recent updates include positive pediatric data for ORLADEYO and licensing deals that expand global reach.

Recent Performance and Market Context

In Q1 2026, BioCryst reported ORLADEYO net revenue of $148.3 million, up 11% year-over-year. Total revenue reached approximately $156.4 million. The company reaffirmed full-year 2026 ORLADEYO guidance of $625–645 million and total revenue of $635–660 million. A strategic restructuring announced in June 2026 discontinued internal drug discovery programs, lowered operating expense guidance, and is expected to improve future profitability without impacting top-line targets.

Why Our Model Shows BioCryst as Undervalued

Our fair value estimate of $17.33 incorporates multiple valuation approaches that emphasize sustainable ORLADEYO growth, margin expansion from cost discipline, and pipeline optionality. Revenue momentum in the rare disease space, combined with analyst consensus targets often exceeding $21, supports a higher intrinsic value than the current market price reflects. The Quality Score of 70/100 further indicates solid fundamentals relative to peers in the healthcare sector.

💡 Theory is good — numbers are better. Get the fair value of any stock worldwide in seconds. Try it free →

Key valuation drivers include:

Double-digit ORLADEYO revenue growth and maintained 2026 guidance.
Operational efficiencies from recent restructuring.
Expanding access through pediatric formulations and international licensing.
Longer-term pipeline catalysts in rare diseases.

Main Risks to Consider

While the upside appears attractive, investors should weigh several risks. BioCryst remains heavily dependent on ORLADEYO as its primary commercial asset, exposing the company to competition in the HAE market. Historical earnings have shown volatility due to one-time charges, and biotech development carries inherent clinical and regulatory uncertainties. Broader sector dynamics and potential dilution could also pressure the share price in the near term.

Balanced Verdict

BioCryst Pharmaceuticals Inc presents a compelling case for undervaluation based on our models. Strong commercial execution on ORLADEYO, combined with proactive cost management, positions the company for improved profitability. The +56% gap to fair value offers a meaningful margin of safety for long-term investors, though position sizing should account for biotech-specific risks. To explore personalized scenarios for BCRX or thousands of other stocks, try the free Fair Value Calculator.

For the latest fair value estimates across 35,000+ stocks using 21 models, visit our fair value calculator anytime.

Frequently Asked Questions

What is BioCryst Pharmaceuticals' main product and revenue outlook?

ORLADEYO (berotralstat) for hereditary angioedema drives the majority of revenue, with full-year 2026 guidance maintained at $625–645 million.

Why does our model show BCRX as undervalued?

Key drivers include robust ORLADEYO growth, cost restructuring, and pipeline expansion that our 21 valuation models weigh favorably against current pricing.

What are the biggest risks for BioCryst Pharmaceuticals stock?

Heavy reliance on a single commercial asset, potential competition in HAE, and historical earnings volatility from one-time charges remain primary concerns.

Sources

Context gathered via live web search while writing this article:

Educational analysis only — not financial advice and not a buy or sell recommendation. Valuations are model-based and may be wrong; past performance does not indicate future results.

Check the fair value of any stock worldwide
26 valuation models · 12,000+ stocks · evidence-based
Start free →

Not financial advice · No buy/sell recommendations · Past performance is not a guarantee of future results.